Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 9, 2026, and June 11, 2026, for Atara Biotherapeutics, Inc. (Nasdaq: ATRA). The filing details the results of the 2026 Annual Meeting of Stockholders and a subsequent appointment to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Corporate Actions
- Board Appointment: On June 11, 2026, the Board appointed Brian Cherry as a Class I director and member of the Audit Committee, effective immediately. Mr. Cherry is deemed independent.
- Director Compensation: Mr. Cherry received an initial equity award of 24,000 restricted stock units (vesting annually over three years) and an annual cash retainer of $55,000 (pro-rated for the partial period).
- Annual Meeting Results: Held on June 9, 2026, the meeting resulted in the following outcomes:
- Election of Directors: AnhCo Nguyen, Ph.D., and Nachi Subramanian were elected. Mr. Subramanian received a significant number of "withheld" votes (993,989) compared to Dr. Nguyen (32,311).
- Executive Compensation: The advisory vote to approve named executive officer compensation was approved (3,526,411 For vs. 44,481 Against).
- Equity Plan Amendment: Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the share reserve by 400,000 shares.
- Auditor Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, or specific risk factors beyond standard governance disclosures.
Key Facts for Investor Verification
- Verify the specific reasons for the high number of "withheld" votes (approx. 27% of votes cast) for director nominee Nachi Subramanian.
- Confirm the total number of shares authorized under the amended 2024 Equity Incentive Plan to assess potential dilution.
- Review the full 2026 Proxy Statement (filed April 24, 2026) for detailed compensation structures and the background of the new director, Brian Cherry.
- Monitor the company's cash position and burn rate, as this 8-K does not disclose current liquidity levels.